Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1052W HIGH $1.09
Volume
23.05 K
Value Traded
138.23 K
Short % Float
1.24%
0%Week
-25.88%1 Month
-7.04%3 Month
-41.9%6 Month
-99.98%5 Year
-99.98%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
7.99 M
EPS (TTM)
-0.20
P/E Ratio
-
Ent. Value
1.27 M
Total Shares
60.61 M
Float Shares
56.54 M
Insiders
6.71%
Institutions
32.04%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
AZTR Catalyst Timeline
Dated clinical, regulatory and corporate events for Azitra Inc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Azitra Inc
179Total events
19Upcoming
22Tier-1 (high impact)
2023 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲DSMB ReviewATR04-484Trial
Safety review committee recommended trial proceed to Cohort 2
EGFR inhibitor (EGFRi)-associated skin rashsource ↗
▲Enrollment CompleteATR04-484Trial
Completion of Cohort 1 in Phase 1/2 trial of ATR04-484
EGFR inhibitor (EGFRi)-associated skin rashsource ↗
▲Enrollment UpdateATR04-484Trial
Enrollment and dosing to begin in Cohort 2
EGFR inhibitor (EGFRi)-associated skin rashsource ↗
◆Additional DataATR-COSFClinical Data
Initial data from ATR-COSF program to be presented
cosmetic applications targeting fine lines and wrinklessource ↗
▲Quarterly UpdateCorporate
Regained compliance with NYSE American continued listing standards
▲Other Regulator MilestoneEx-US Regulatory
Regained compliance with NYSE American continued listing standards
▲Preclinical PoCATR-COSFPreclinical
First preclinical data from ATR-COSF demonstrating breakthrough repeat-dose distribution, controlled delivery into targeted skin layers and anti-wrinkle activity in ex vivo human skin
cosmetic and skincare applicationssource ↗
●Enrollment UpdateATR-04Trial
Continued enrollment of the first cohort in Phase 1/2 trial
EGFR inhibitor-associated rashsource ↗
▼Enrollment PausedATR-12Trial
Plans to strategically pause further enrollment in Phase 1b study
Netherton syndromesource ↗
▲Preclinical PoCATR-COSFPreclinical
Repeat dose ex vivo distribution and anti-wrinkle results for ATR-COSF
cosmetic ingredient for anti-wrinkle and skin elasticitysource ↗
◆Trial InitiationATR-COSFTrial
Human cosmetic application study planned to start
cosmetic and skincare applicationssource ↗
▲Preclinical PoCATR-COSFPreclinical
First preclinical data from ATR-COSF demonstrating repeat-dose distribution and anti-wrinkle activity
cosmetic/skincare (anti-wrinkle)source ↗
●Enrollment UpdateATR-04Trial
Continued enrollment of first cohort in Phase 1/2 trial
EGFR inhibitor-associated rashsource ↗
▲Enrollment UpdateATR-04Trial
Continued enrollment and addition of MD Anderson Cancer Center as clinical site
EGFR inhibitor-associated rashsource ↗
▼Enrollment PausedATR-12Trial
Pause further enrollment in ATR-12 trial to conserve capital
Netherton syndromesource ↗
●Oral PresentationATR-01Presentation
ATR-01 preclinical data presented at ASGCT 2026
Ichthyosis Vulgarissource ↗
◆Poster PresentationATR-01Presentation
Poster presentation at ASGCT 2026 highlighting preclinical data for ATR01-616
ichthyosis vulgarissource ↗
▲Patent GrantedATR-12IP / Competition
U.S. Patent 12,606,610 B2 issued for ATR-12
Netherton syndromesource ↗
▼Equity OfferingCorporate
Pricing of private placement financing of up to approximately $31.4 million
▲Equity OfferingCorporate
Raised $10.5 million with up to $21 million additional through warrant exercise
▲Enrollment UpdateATR-04Trial
Addition of MD Anderson Cancer Center as clinical site for Phase 1/2 trial of ATR-04
EGFR inhibitor-associated rashsource ↗
◆Quarterly UpdateCorporate
Special Meeting adjourned due to lack of quorum, reconvened on March 6, 2026
▲Enrollment UpdateATR-04Trial
Added MD Anderson Cancer Center as clinical site for ATR-04 trial
EGFRi-associated skin rashsource ↗
◆Topline ReadoutATR-12Clinical Data
Topline data of Phase 1b trial with ATR-12 in Netherton syndrome patients
Netherton syndromesource ↗
▲Timing GuidancePresentation
NYSE American approved Azitra's plan to regain compliance with continued listing standards
◆Oral PresentationATR-01Presentation
Virtual presentation of ATR-01 preclinical data at BIO-Europe conference
ichthyosis vulgarissource ↗
◆Oral PresentationPresentation
Dermatologic Rare Disease Panel at Maxim Growth Summit
Netherton syndrome, Recessive Epidermolysis Bullosa (RDEB)source ↗
▲Preclinical PoCATR-01Preclinical
Positive preclinical data for ATR-01 showing functional filaggrin production and skin barrier repair
ichthyosis vulgarissource ↗
▼Going ConcernCorporate
Received NYSE American non-compliance notice for stockholders' equity deficiency
◆Oral PresentationPresentation
Virtual presentation at H.C. Wainwright 27th Annual Global Investment Conference
▲Safety Data UpdateATR-12Clinical Data
Promising safety results for Phase 1b trial of ATR-12 in Netherton syndrome
Netherton syndromesource ↗
▲First Patient DosedATR-04Trial
First patient dosed in Phase 1/2 trial of ATR-04 for EGFRi-associated dermal toxicity
EGFR inhibitor-associated dermal toxicitysource ↗
▲First Patient DosedATR04-484Trial
First patient dosed in Phase 1/2 trial of ATR04-484 for EGFRi-associated rash
EGFR inhibitor-associated rashsource ↗
▼Reverse Stock SplitCorporate
Reverse stock split at ratio 1-for-6.66 effective August 21, 2025
▲Safety Data UpdateATR-12Clinical Data
Initial safety results and 50% enrollment of Phase 1b trial of ATR-12
Netherton syndromesource ↗
●Poster PresentationATR-04Presentation
Poster detailing Phase 1/2 trial of ATR-04 accepted at 2025 ASCO Annual Meeting
EGFR inhibitor-associated rashsource ↗
Past FDA Catalysts and PDUFA Decisions
How AZTR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-11 | ATR01-616 | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D23 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 87%
Micro Cap(rank 573 of 658)
Percentile Rank
Azitra Inc faces pipeline headwinds (23/100), with $32M risk-adjusted pipeline value, led by ATR04-484 in EGFR Inhibitor-associated Rash (Phase 1), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ATR04-484 Small moleculeNCT06830863 | EGFR Inhibitor-associated Rash | Phase 1 | RECRUITING | 32 | Feb 15, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every AZTR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ATR-12 | Netherton syndrome | Phase 1b | 2025-09-04 | Azitra's Phase 1b clinical trial of ATR-12 for Netherton syndrome reported promising safety results, indicating a favorable safety profile for the treatment in adult patients, although specific efficacy metrics were not disclosed in the announcement.Read More | Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Salva Francisco D.Director, Officer (President and CEO) | Buy | 500 500 held | $0.00 | 03/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AZTR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in AZTR for Q2 2026. | ||||
AZTR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AZTR ranks across every disease it competes in
Competitive Position is a premium feature
See how AZTR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAZTR News
AZTR▼ -6.6%on this news
Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance
Azitra, Inc. has received clearance from its safety review committee to advance to Cohort 2 in its Phase 1/2 clinical trial for ATR-04-484, aimed at treating EGFR inhibitor-associated skin rash. The trial's first cohort showed positive safety data, prompting further enrollment. ATR-04-484 is being developed as a live biotherapeutic to address a significant side effect affecting cancer patients.
Read more →AZTRAzitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Azitra, Inc. will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. Dr. Travis Whitfill will discuss the company's recent progress, including updates on the ATR-COSF program and ongoing Phase 1/2 clinical trials for ATR-04. The presentation will also include one-on-one meetings with investors to highlight Azitra's strategies and milestones.
Read more →AZTRAzitra, Inc. Regains Compliance with NYSE American Continued Listing Standards
Azitra, Inc. has announced that it has regained compliance with NYSE American listing standards, resolving previous deficiencies. The company will no longer be marked as noncompliant and is committed to maintaining strong financial governance. CEO Francisco Salva highlighted the focus on advancing their clinical programs, particularly ATR-COSF and ATR-04, which aim to create value for shareholders.
Read more →AZTRAzitra, Inc. Announces Q2 2026 Results and Provides Business Updates
Azitra, Inc. reported its Q2 2026 financial results, highlighting significant advancements in its clinical programs, particularly ATR-COSF and ATR-04. The company showcased promising preclinical data for ATR-COSF, which aims to address skin aging, and continued enrollment in its Phase 1/2 trial for ATR-04 targeting EGFR inhibitor-associated rash. Despite a net loss increase, Azitra is strategically focusing on high-potential initiatives.
Read more →AZTRAzitra, Inc. Announces Breakthrough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity
Azitra, Inc. has announced promising results for its ATR-COSF program, which utilizes a recombinant human protein derived from S. epidermis. The ex vivo data indicates enhanced distribution and elasticity, positioning the formulation as a valuable cosmetic ingredient. This breakthrough could lead to advancements in cosmetic applications.
Read more →AZTRAzitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity
Azitra, Inc. announced positive results from ex vivo studies on its ATR-COSF program, which utilizes a recombinant human protein to improve skin elasticity and reduce wrinkles. The studies showed enhanced distribution of rHDfilaggrin in human skin and demonstrated its effectiveness in increasing skin firmness. The company plans to continue optimizing formulations and advance to human trials.
Read more →AZTR▲ +10.3%on this news
Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
Azitra, Inc. has announced a strategic reorientation aimed at growth, highlighted in a letter from CEO Francisco Salva. The company plans to leverage advancements in synthetic biology and artificial intelligence to enhance its product pipeline, particularly through initiatives like ATR-COSF that target the cosmetic ingredient market. The successful financing in March 2026 raised $10.5 million, enabling these opportunities while also posing risks due to paused clinical trials. Azitra aims to create value for shareholders by exploring broader applications in biotechnology products and recombinant proteins.
Read more →AZTR▼ -7%on this newsshared move
Azitra, Inc. to Present at 2026 BIO International Convention
Azitra, Inc. will present its recent developments at the 2026 BIO International Convention in San Diego, where Travis Whitfill, Ph.D., is scheduled to give a presentation. The highlights will include advancements in Azitra's pipeline, particularly their protein and peptide technologies for the cosmetic market and the clinical programs for Netherton syndrome and EGFR inhibitor associated rash. The company aims to showcase its innovative therapies and secure potential investment and partnership opportunities during the event.
Read more →AZTRAzitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
Azitra, Inc. announced the adjournment of its 2026 Annual Meeting due to insufficient shareholder representation to meet quorum requirements. Originally scheduled for June 4, 2026, the meeting will be reconvened on June 15, 2026. Shareholders are urged to submit their voting proxies prior to the reconvened meeting. The company specializes in innovative therapies for precision dermatology, including treatments for rare skin conditions.
Read more →AZTRAzitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting
Azitra, Inc. announced its intention to adjourn the 2026 Annual Meeting of stockholders originally scheduled for June 4, 2026, reconvening it on June 15, 2026. This decision comes due to a minor administrative delay in mailing proxy materials, allowing stockholders additional time to submit their votes. The meeting will continue to be held virtually, facilitating participation from stockholders who can engage through a live webcast. The proposals at the reconvened meeting will remain unchanged from the original agenda.
Read more →AZTRAzitra, Inc. Announces Q1 2026 Results and Provides Business Updates
Azitra, Inc. reported strong Q1 2026 results, highlighting advancements in its clinical trials and the launch of a new cosmeceutical initiative. The company has expanded its Phase 1/2 trial for ATR-04 by partnering with MD Anderson Cancer Center. Additionally, Azitra received a new patent for ATR-12, which is in a Phase 1b trial for Netherton syndrome, enhancing its market position.
Read more →AZTRAzitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program
Azitra, Inc. has announced the issuance of a new U.S. patent for its lead product candidate, ATR-12, which is currently undergoing a Phase 1b clinical trial for Netherton syndrome. The patent provides broad protections for the engineered strain of S. epidermidis that expresses a fragment of the human LEKTI protein. This development is significant as Netherton syndrome currently has no approved treatments, highlighting the potential impact of ATR-12 on patient care.
Read more →AZTR▲ +11.1%on this news
Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris
Azitra, Inc. presented new preclinical data for its ATR-01 program at ASGCT 2026, demonstrating its potential to treat ichthyosis vulgaris by delivering functional filaggrin into the skin. The engineered biotherapeutic candidate ATR01-616 showed significant efficacy in reducing transepidermal water loss and restoring skin barrier function. The findings support the program's advancement toward clinical trials.
Read more →AZTR▲ +28.8%on this news· ran to +107% by day 1
Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million
Azitra, Inc. has announced a private placement financing agreement to raise up to approximately $31.4 million, comprising $10.5 million in initial funding and an additional $20.9 million contingent upon the exercise of warrants by investors. The funds are intended to support the development of innovative protein and peptide technologies for the cosmeceutical market, leveraging Azitra's microbial genetic engineering platform. Notably, the financing involves several institutional investors and company insiders. The transaction is subject to customary closing conditions, including stockholder approval.
Read more →AZTRAzitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement
Azitra, Inc. has received a notice of non-compliance from the NYSE American, indicating it does not meet the required stockholders' equity standards. The company reported losses over the past fiscal years, prompting this action from the Exchange. Azitra submitted a plan to regain compliance, which has been accepted, and it has until April 1, 2027, to meet these requirements. The notice has no immediate effect on trading but highlights concerns about the company's financial viability as indicated by an auditor's substantial doubt regarding its ability to continue operations.
Read more →AZTRAzitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders
Azitra, Inc. has announced the cancellation of its special meeting of stockholders originally scheduled for February 6, 2026, which was adjourned due to insufficient quorum. The meeting was rescheduled for March 6, 2026. Azitra is focused on developing therapies for precision dermatology, including treatments for Netherton syndrome and EGFR inhibitor-associated rash.
Read more →AZTR▼ -6.1%on this newsshared move
Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates
Azitra, Inc. reported its financial results for FY 2025, highlighting significant advancements in its clinical trials, particularly for ATR-04 and ATR-12. The company received positive feedback at the ASCO Annual Meeting regarding its innovative therapies targeting dermatological conditions. Looking ahead, Azitra anticipates key milestones in 2026, including topline data from ongoing studies.
Read more →AZTRAzitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash
Azitra, Inc. has announced the inclusion of MD Anderson Cancer Center as a clinical site for its Phase 1/2 trial of ATR-04, a treatment for EGFRi-associated skin rash. This expansion is expected to accelerate patient enrollment and treatment milestones. The trial evaluates the safety and tolerability of ATR04-484, a live biotherapeutic product candidate designed to mitigate skin toxicity in cancer patients. The FDA has granted Fast Track designation to ATR-04, highlighting its potential impact on patient care.
Read more →AZTR▲ +7.2%on this newsshared move
Azitra, Inc. to Present at BIO Investment & Growth Summit
Azitra, Inc. has announced its participation in the BIO Investment & Growth Summit scheduled for March 2-3, 2026. The presentation will cover updates on its clinical pipeline, including therapy candidates ATR-12 and ATR-04, which focus on dermatological conditions with significant unmet needs. Azitra's management will also engage in one-on-one meetings with investors to discuss the company's growth strategy and recent milestones. Key aspects of its proprietary platform and the implications of their ongoing clinical trials will be highlighted during this event.
Read more →AZTRAzitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
Azitra, Inc. has announced the adjournment of its Special Meeting originally scheduled for February 6, 2026, due to a lack of quorum. The meeting will reconvene on March 6, 2026, to solicit additional votes on key proposals. Stockholders are encouraged to participate and vote ahead of the reconvened meeting.
Read more →About Azitra Inc
Headquarters21 BUSINESS PARK DRIVE, SUITE 6, BRANFORD, CT, 06405
Founded20-06-2023
BIOPHARMAWATCH ELITE PLUS
Trade the next AZTR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime